UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 27, 2024

ROCKET LAB USA, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

001-39560 (Commission File Number) 98-1550340 (IRS Employer Identification No.)

3881 McGowen Street
Long Beach, California
(Address of Principal Executive Offices)

90808 (Zip Code)

Registrant's Telephone Number, Including Area Code: 714 465-5737

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Securities registered pursuant to Section 12(b) of the Act:

Trading

Title of each class Symbol(s) Name of each exchange on which registered

Common Stock, par value \$0.0001 per share RKLB The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 2.02 Results of Operations and Financial Condition.

On February 27, 2024, Rocket Lab USA, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 (the "Section") of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit	Description
99.1	Press Release of Rocket Lab USA, Inc., dated February 27, 2024
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ROCKET LAB USA, INC.

Date: February 27, 2024 By: /s/ Adam Spice

Adam Spice

Chief Financial Officer





Rocket Lab Announces Fourth Quarter and Full Year 2023 Financial Results, Issues Guidance for the First Quarter 2024 Including Sequential Revenue Growth Greater than 50 Percent

Long Beach, California. February 27, 2024 – Rocket Lab USA, Inc. (Nasdaq: RKLB) ("Rocket Lab" or "the Company"), a global leader in launch services and space systems, today shared the financial results for fiscal fourth quarter and full year, ended December 31, 2023.

Rocket Lab founder and CEO, Peter Beck, said: "Rocket Lab had another strong year in 2023 across our launch and space systems businesses. We grew revenue 16% year-on year, while expanding our GAAP and non-GAAP gross margins by 12.0 and 6.9 percentage points, respectively, and rounded out the fourth quarter with our largest contract – an award up to \$515 million from the Space Development Agency which will see us act as prime contractor for the first time to build 18 satellites for the Tranche 2 Transport Layer-Beta. We also reached a new annual launch record, with ten Electron missions flown in 2023. It was also a record year for securing Electron and HASTE contracts, with 25 new orbital and suborbital missions signed in 2023. We rounded out the year with some significant milestones for Neutron development, including the opening of a new manufacturing complex in Baltimore that will support the production of Neutron's carbon composite structures, and Archimedes engine development entered the final stages ahead of the first hot fire. Continuing this strong momentum, we started 2024 off strong with the issuance of \$355 million in convertible senior notes, adding additional funding to the Rocket Lab balance sheet at an attractive cost of capital and enabling us to take advantage of potential M&A as well as other strategic growth investment opportunities."

Fourth Quarter 2023 Business Highlights:

- Selected as prime contractor by the Space Development Agency for a \$515 million contract to design, build and operate 18 satellites for the Tranche 2 Transport Layer-Beta.
- Electron successfully returned to flight in the fourth quarter, deploying a synthetic aperture radar satellite to orbit for Japanese constellation operator iQPS.
- Closed 2023 with a record number of 25 launches signed across Electron and HASTE.
- Progressed major infrastructure milestones at Launch Complex 3 for Neutron, including foundations for the launch mount, water tower and liquid oxygen tanks.
- Established a Space Structures Complex in the former Lockheed Martin Vertical Launch Building in Middle River, Maryland to support the development and manufacture of carbon composite spacecraft structures and components, as well as the long-term supply of carbon composite structures for Neutron.
- Refinanced our \$100M term loan facility with Hercules Capital, into a larger, longer duration and cost-effective \$120M equipment lending facility with Trinity Capital.



Business Highlights Since December 31, 2023:

- Successfully launched two Electron missions, including a Space Situational Awareness mission for Spire and NorthStar, as well as an orbital debris observation demonstration mission for Astroscale Japan Inc.
- Progressed Electron's reusability program with a successful ocean splashdown and recovery in January 2024, bringing Electron's first stage back in the best condition yet.
- Entered the commissioning phase at the Archimedes Test Complex at NASA Stennis Space Center in preparation for Neutron engine hot fires.
- Closed an upsized offering of \$355 million convertible senior notes to open up a mix of opportunities including potential M&A and other strategic growth and scaling investments.
- Successful re-entry of Rocket Lab-built in-space manufacturing satellite developed for Varda Space Industries. The successful reentry marked the completion of the first commercial in-space manufacturing demonstration.

First Quarter 2024 Guidance

For the first quarter of 2024, Rocket Lab expects:

- Revenue between \$92 million and \$98 million.
- Space Systems revenue between \$60 million and \$65 million.
- Launch Services revenue between \$32 million and \$33 million.
- GAAP Gross Margins between 24% and 26%.
- Non-GAAP Gross Margins between 29% and 31%.
- GAAP Operating Expenses between \$73 million and \$75 million.
- Non-GAAP Operating Expenses between \$62 million and \$64 million.
- Expected Interest Expense (Income), net \$1.5 million.
- Adjusted EBITDA loss of \$28 million to \$30 million.
- Basic Shares Outstanding of 490 million.

See "Use of Non-GAAP Financial Measures" below for an explanation of our use of Non-GAAP financial measures, and the reconciliation of historical Non-GAAP measures to the comparable GAAP measures in the tables attached to this press release. We have not provided a reconciliation for the forward-looking Non-GAAP Gross Margin, Non-GAAP Operating Expenses or Adjusted EBITDA expectations for Q1 2024 described above because, without unreasonable efforts, we are unable to predict with reasonable certainty the amount and timing of adjustments that are used to calculate these non-GAAP financial measures, particularly related to stock-based compensation and its related tax effects. Stock-based compensation is currently expected to range from \$12 million to \$13 million in Q1 2024.



Conference Call Information

Rocket Lab will host a conference call for investors at 2 p.m. PT (5 p.m. ET) today to discuss these business highlights and financial results for our fourth quarter, to provide our outlook for the first quarter, and other updates.

The live webcast and a replay of the webcast will be available on Rocket Lab's Investor Relations website: https://investors.rocketlabusa.com/events-and-presentations/events

About Rocket Lab

Founded in 2006, Rocket Lab is an end-to-end space company with an established track record of mission success. We deliver reliable launch services, satellite manufacture, spacecraft components, and on-orbit management solutions that make it faster, easier and more affordable to access space. Headquartered in Long Beach, California, Rocket Lab designs and manufactures the Electron small orbital launch vehicle and the Photon satellite platform and is developing the Neutron launch vehicle for large spacecraft and constellation deployment. From its first orbital launch in January 2018 to date, Rocket Lab's Electron launch vehicle has become the second most frequently launched U.S. rocket annually and has delivered 177 satellites to orbit for private and public sector organizations, enabling operations in national security, scientific research, space debris mitigation, Earth observation, climate monitoring, and communications. Rocket Lab's Photon spacecraft platform has been selected to support NASA missions to the Moon and Mars, as well as the first private commercial mission to Venus. Rocket Lab has three launch pads at two launch sites, including two launch pads at a private orbital launch site located in New Zealand and a third launch site in Virginia, USA. To learn more, visit www.rocketlabusa.com.

+ Rocket Lab Investor Relations Contact Colin Canfield investors@rocketlabusa.com

+ Rocket Lab Media Contact Morgan Bailey media@rocketlabusa.com



+ FORWARD LOOKING STATEMENTS

This press release may contain certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release, including statements regarding our expectations of financial results for the first quarter of 2024, strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. Words such as, but not limited to, "anticipate," "aim," "believe," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forwardlooking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on Rocket Lab's current expectations and beliefs concerning future developments and their potential effects. These forward-looking statements involve a number of risks, uncertainties (many of which are beyond Rocket Lab's control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including risks related to delays and disruptions in expansion efforts; delays in the development of our Neutron rocket; our dependence on a limited number of customers; the harsh and unpredictable environment of space in which our products operate which could adversely affect our launch vehicle and spacecraft; increased competition in our industry due in part to rapid technological development; technological change in our industry which we may not be able to keep up with or which may render our services uncompetitive; average selling price trends; general economic uncertainty and turbulence which could impact our customers' ability to pay what we are owed; failure of our launch vehicles, spacecraft and components to operate as intended either due to our error in design. in engineering, in production or through no fault of our own; launch schedule disruptions; supply chain disruptions, product delays or failures; design and engineering flaws; launch failures; natural disasters and epidemics or pandemics; any inability to effectively integrate recently acquired assets; a US government shutdown or delays in government funding; changes in governmental regulations including with respect to trade and export restrictions, or in the status of our regulatory approvals or applications; or other events that force us to cancel or reschedule launches, including customer contractual rescheduling and termination rights; risks that acquisitions may not be completed on the anticipated time frame or at all or do not achieve the anticipated benefits and results; and the other risks detailed from time to time in Rocket Lab's filings with the Securities and Exchange Commission (the "SEC"), including under the heading "Risk Factors" in Rocket Lab's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the SEC on March 7, 2023, and elsewhere. There can be no assurance that the future developments affecting Rocket Lab will be those that we have anticipated. Except as required by law, Rocket Lab is not undertaking any obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.



+ USE OF NON-GAAP FINANCIAL MEASURES

We supplement the reporting of our financial information determined under Generally Accepted Accounting Principles in the United States of America ("GAAP") with certain non-GAAP financial information. The non-GAAP financial information presented excludes certain significant items that may not be indicative of, or are unrelated to, results from our ongoing business operations. We believe that these non-GAAP measures provide investors with additional insight into the company's ongoing business performance. These non-GAAP measures should not be considered in isolation or as a substitute for the related GAAP measures, and other companies may define such measures differently. We encourage investors to review our financial statements and publicly filed reports in their entirety and not to rely on any single financial measure. Reconciliation of the non-GAAP financial information to the corresponding GAAP measures for the historical periods disclosed are included at the end of the tables in this press release. We have not provided a reconciliation for forward-looking non-GAAP financial measures because, without unreasonable efforts, we are unable to predict with reasonable certainty the amount and timing of adjustments that are used to calculate these non-GAAP financial measures, particularly related to stock-based compensation and its related tax effects. The following definitions are provided:

+ ADJUSTED EDITDA

EBITDA is defined as earnings before interest, taxes, depreciation and amortization. Adjusted EBITDA further excludes items of income or loss that we characterize as unrepresentative of our ongoing operations. Such items are excluded from net income or loss to determine Adjusted EBITDA. Management believes this measure provides investors meaningful insight into results from ongoing operations.

+ OTHER NON-GAAP FINANCIAL MEASURES

Non-GAAP gross profit, research and development, net, selling, general and administrative, operating expenses, operating loss and total other income (expense), net, further excludes items of income or loss that we characterize as unrepresentative of our ongoing operations. Such items are excluded from the applicable GAAP financial measure. Management believes these non-GAAP measures provide investors meaningful insight into results from ongoing operations.



ROCKET LAB U.S.A., INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2023 AND 2022

(unaudited; in thousands, except share and per share data)

2023 59,991		2022		2022		
59 991				2023		2022
57,771	\$	51,762	\$	244,592	\$	210,996
44,499		49,932		193,183		192,006
15,492		1,830		51,409		18,990
37,488		15,018		119,054		65,168
25,887		24,035		110,273		89,026
63,375		39,053		229,327		154,194
(47,883)		(37,223)		(177,918)		(135,204)
(1,405)		(892)		(4,248)		(7,799)
(394)		(488)		(470)		(4,435)
_		_		_		13,482
196		385		3,715		1,010
(1,603)		(995)		(1,003)		2,258
(49,486)		(38,218)		(178,921)		(132,946)
(1,011)		1,010		(3,650)		(2,998)
(50,497)	\$	(37,208)	\$	(182,571)	\$	(135,944)
(0.10)	\$	(0.08)	\$	(0.38)	\$	(0.29)
486,959,454		473,644,862		481,768,060		466,214,095
	44,499 15,492 37,488 25,887 63,375 (47,883) (1,405) (394) ————————————————————————————————————	44,499 15,492 37,488 25,887 63,375 (47,883) (1,405) (394) — 196 (1,603) (49,486) (1,011) (50,497) \$ (0.10) \$	44,499 49,932 15,492 1,830 37,488 15,018 25,887 24,035 63,375 39,053 (47,883) (37,223) (1,405) (892) (394) (488) — — 196 385 (1,603) (995) (49,486) (38,218) (1,011) 1,010 (50,497) \$ (37,208) (0.10) \$ (0.08)	44,499 49,932 15,492 1,830 37,488 15,018 25,887 24,035 63,375 39,053 (47,883) (37,223) (1,405) (892) (394) (488) — — 196 385 (1,603) (995) (49,486) (38,218) (1,011) 1,010 (50,497) \$ (0.10) \$ (0.08) \$	44,499 49,932 193,183 15,492 1,830 51,409 37,488 15,018 119,054 25,887 24,035 110,273 63,375 39,053 229,327 (47,883) (37,223) (177,918) (1,405) (892) (4,248) (394) (488) (470) — — — 196 385 3,715 (1,603) (995) (1,003) (49,486) (38,218) (178,921) (1,011) 1,010 (3,650) (50,497) \$ (37,208) \$ (182,571) (0.10) \$ (0.08) \$ (0.38)	44,499 49,932 193,183 15,492 1,830 51,409 37,488 15,018 119,054 25,887 24,035 110,273 63,375 39,053 229,327 (47,883) (37,223) (177,918) (1,405) (892) (4,248) (394) (488) (470) — — — 196 385 3,715 (1,603) (995) (1,003) (49,486) (38,218) (178,921) (1,011) 1,010 (3,650) (50,497) \$ (37,208) \$ (0.10) \$ (0.08) \$ (0.38) \$



ROCKET LAB U.S.A., INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AS OF DECEMBER 31, 2023 AND 2022

(unaudited; in thousands, except share and per share data)

(unaudited; in thousands, except share and per share	data)	Decem	ber 31,	
		2023		2022
Assets				
Current assets:				
Cash and cash equivalents	\$	162,518	\$	242,515
Marketable securities, current		82,255		229,276
Accounts receivable, net		35,176		36,572
Contract assets		12,951		9,451
Inventories		107,857		92,279
Prepaids and other current assets		66,949		52,201
Assets held for sale		9,016		_
Total current assets		476,722		662,294
Non-current assets:				
Property, plant and equipment, net		145,409		101,514
Intangible assets, net		68,094		79,692
Goodwill		71,020		71,020
Right-of-use assets - operating leases		59,401		35,239
Right-of-use assets - finance leases		14,987		15,614
Marketable securities, non-current		79,247		9,193
Restricted cash		3,916		3,356
Deferred income tax assets, net		3,501		3,898
Other non-current assets		18,914		7,303
Total assets	\$	941,211	\$	989,123
Liabilities and Stockholders' Equity	-			
Current liabilities:				
Trade payables	\$	29,303	\$	12,084
Accrued expenses		5,590		8,723
Employee benefits payable		16,342		8,634
Contract liabilities		139,338		108,344
Current installments of long-term borrowings		17,764		2,906
Other current liabilities		15,036		22,249
Total current liabilities		223,373		162,940
Non-current liabilities:		223,373		102,510
Long-term borrowings, excluding current installments		87,587		100,043
Non-current operating lease liabilities		56,099		34,266
Non-current finance lease liabilities		15,238		15,568
Deferred tax liabilities		426		95
Other non-current liabilities		3,944		3,005
Total liabilities		386,667		315,917
COMMITMENTS AND CONTINGENCIES		300,007		313,717
Stockholders' equity:				
Common stock, \$0.0001 par value; authorized shares: 2,500,000,000; issued and outstanding shares:				
488,923,055 and 475,356,517 at December 31, 2023 and December 31, 2022, respectively		49		48
Additional paid-in capital		1,176,484		1,112,977
Accumulated deficit		(623,526)		(440,955)
Accumulated other comprehensive income		1,537		1,136
Total stockholders' equity		554,544		673,206
Total liabilities and stockholders' equity	\$	941,211	\$	989,123
Tomi manifeld and dioeknotaerd equity	Ψ	771,411	Ψ	707,123





ROCKET LAB U.S.A., INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022

(unaudited; in thousands)

(unaudited; in thousands)	Years Ended	Decembe	r 31.
	2023		2022
CASH FLOWS FROM OPERATING ACTIVITIES:			
Net loss	\$ (182,571)	\$	(135,944)
Adjustments to reconcile net loss to net cash used in operating activities:			
Depreciation and amortization	29,744		29,947
Stock-based compensation expense	53,461		55,649
(Gain) loss on disposal of assets	(111)		923
Loss on extinguishment of long-term debt	1,732		_
Amortization of debt issuance costs and discount	2,904		2,827
Noncash lease expense	5,787		3,199
Noncash income associated with liability-classified warrants	_		(13,482)
Change in the fair value of contingent consideration	1,343		_
Accretion of marketable securities purchased at a discount	(4,571)		(1,395)
Deferred income taxes	708		(576)
Changes in operating assets and liabilities:			
Accounts receivable, net	1,452		(9,430)
Contract assets	(3,501)		(7,545)
Inventories	(15,562)		(25,964)
Prepaids and other current assets	(14,586)		(15,059)
Other non-current assets	(11,470)		(7,072)
Trade payables	15,585		(2,129)
Accrued expenses	(3,275)		(3,518)
Employee benefits payables	5,484		2,108
Contract liabilities	30,992		22,661
Other current liabilities	(7,563)		1,280
Non-current lease liabilities	(5,076)		(3,686)
Other non-current liabilities	227		668
Net cash used in operating activities	(98,867)		(106,538)
CASH FLOWS FROM INVESTING ACTIVITIES:			
Purchases of property, equipment and software	(54,707)		(42,412)
Proceeds on disposal of assets, net	3,660		_
Cash paid for business combinations and asset acquisitions, net of acquired cash and restricted cash	(18,966)		(65,824)
Purchases of marketable securities	(207,266)		(259,567)
Maturities of marketable securities	269,204		21,724
Sale of marketable securities	20,093		_
Net cash provided by (used in) investing activities	 12,018		(346,079)
CASH FLOWS FROM FINANCING ACTIVITIES:	,		(= 10,012)
Proceeds from the exercise of stock options and public warrants	2,444		3,874
Proceeds from Employee Stock Purchase Plan	4,988		4,380
Proceeds from sale of employees restricted stock units to cover taxes	15,995		31,166
Minimum tax withholding paid on behalf of employees for restricted stock units	(15,722)		(31,164)
Tax payment for net settled option shares	(13,722)		(444)
Payment of contingent consideration	(1,000)		(5,500)
Finance lease principal payments	(336)		(271)
Proceeds from secured term loan	110,000		(2/1)
Repayments on secured term loan	(107,573)		_
Payment of debt issuance costs	(1,427)		_
·	 		2.041
Net cash provided by financing activities	7,369		2,041
Effect of exchange rate changes on cash and cash equivalents	 (70, 437)		4,372
Net decrease in cash and cash equivalents and restricted cash	(79,437)		(446,204)
Cash and cash equivalents, and restricted cash, beginning of period	 245,871		692,075
Cash and cash equivalents, and restricted cash, end of period	\$ 166,434	\$	245,871





ROCKET LAB U.S.A., INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES FOR THE THREE MONTHS AND YEARS ENDED DECEMBER 31, 2023 AND 2022 (unaudited; in thousands)

The tables provided below reconcile the non-GAAP financial measures Adjusted EBITDA, Non-GAAP gross profit, Non-GAAP research and development, net, Non-GAAP selling, general and administrative, Non-GAAP operating expenses, Non-GAAP operating loss and Non-GAAP total other income (expense), net with the most directly comparable GAAP financial measures. See above for additional information on the use of these non-GAAP financial measures.

	Three Months End	led I	December 31,	Years Ended D)ecem	ber 31,
	2023		2022	2023		2022
NET LOSS	\$ (50,497)	\$	(37,208)	\$ (182,571)	\$	(135,944)
Depreciation	4,571		4,809	16,034		16,720
Amortization	3,596		3,548	13,710		13,227
Stock-based compensation expense	10,063		12,337	53,461		55,649
Transaction costs	30		144	341		649
Interest expense, net	1,405		892	4,248		7,799
Change in fair value of liability classified warrants	_		_	_		(13,482)
Change in fair value of contingent consideration	205		(200)	1,343		_
Performance reserve escrow	31		1,895	5,457		7,579
Amortization of inventory step-up	_		_	_		2,618
(Benefit) provision for income taxes	1,011		(1,010)	3,650		2,998
Loss on foreign exchange	394		488	470		4,435
Accretion of marketable securities and cash equivalents purchased at						
a discount	(1,179)		(1,092)	(4,780)		(1,696)
(Gain) loss on disposal of assets	(351)		891	(111)		923
Employee retention credit	_		_	(3,841)		_
Loss on extinguishment of debt	1,732		_	1,732		_
ADJUSTED EBITDA	\$ (28,989)	\$	(14,506)	\$ (90,857)	\$	(38,525)



GAAP Gross profit \$ 15,492 \$ 1,830 \$ 51,409 \$ Stock-based compensation 2,196 3,857 12,521 Amortization of purchased intangibles 1,710 1,710 6,839 Amortization of inventory step-up — — — Performance reserve secrow 1 114 210 Employee retention credit — — (2,130) Non-GAAP Gross profit \$ 19,399 \$ 7,511 \$ 68,849 Non-GAAP Gross margin 32,3% 14.5% 28.1% Stock-based compensation (3,828) (4,442) (21,721) Amortization of purchased intangibles and favorable lease (314) (9) (647) Employee retention credit — — 631 Non-GAAP Research and development, net \$ 33,346 \$ 10,567 \$ 97,317 \$ Stock-based compensation (4,039) (4,038) (11,278) \$ Apply Step Step Step Step Step Step Step Step	2022 18,990 17,948 4,782 2,618 456 — 44,794 21.2 65,168 (21,127 (3,342 — 40,699 89,026 (16,574 (4,401 (649 (7,123)
Stock-based compensation 2,196 3,857 12,521 Amortization of purchased intangibles 1,710 1,710 6,839 Amortization of purchased intangibles 1,710 1,710 6,839 Amortization of inventory step-up — — — Performance reserve secrow 1 114 210 Employee retention credit — — — (2,130) Non-GAAP Gross profit \$ 19,399 \$ 7,511 \$ 68,849 \$ Non-GAAP Gross margin 32,3% 14.5% 28.1% GAAP Research and development, net \$ 37,488 \$ 15,018 \$ 119,054 \$ Stock-based compensation (3,828) (4,442) (21,721) Amortization of purchased intangibles and favorable lease (314) (9) (647) Employee retention credit — — — 631 Non-GAAP Research and development, net \$ 33,346 \$ 10,567 \$ 97,317 \$ GAAP Selling, general and administrative \$ 25,887 \$ 24,035 \$ 110,273 \$	17,948 4,782 2,618 456 — 44,794 21.2 65,168 (21,127 (3,342 — 40,699 89,026 (16,574 (4,401 (649)
Amortization of purchased intangibles 1,710 1,710 6,839 Amortization of inventory step-up — — — Performance reserve escrow 1 114 210 Employee retention credit — — — (2,130) Non-GAAP Gross profit \$ 19,399 \$ 7,511 \$ 68,849 \$ Non-GAAP Gross margin 32,3% 14,5% 28.1% GAAP Research and development, net \$ 37,488 \$ 15,018 \$ 119,054 \$ Stock-based compensation (3,828) (4,442) (21,721) Amortization of purchased intangibles and favorable lease (314) (9) (647) Employce retention credit — — — 631 631 Non-GAAP Research and development, net \$ 33,346 \$ 10,567 \$ 97,317 \$ \$ GAAP Selling, general and administrative \$ 25,887 \$ 24,035 \$ 110,273 \$ GAAP Selling, general and administrative \$ 25,887 \$ 24,035 \$ 110,273 \$ Stock-based compensation (4,039) (4,038)	4,782 2,618 456 44,794 21.2 65,168 (21,127 (3,342 40,699 89,026 (16,574 (4,401) (649)
Amortization of inventory step-up	2,618 456 — 44,794 21.2 65,168 (21,127 (3,342 — 40,699 89,026 (16,574 (4,401) (649
Performance reserve escrow	456 ————————————————————————————————————
Employee retention credit	44,794 21.2 65,168 (21,127 (3,342 — 40,699 89,026 (16,574 (4,401 (649)
Non-GAAP Gross profit S 19,399 S 7,511 S 68,849 S Non-GAAP Gross margin 32.3% 14.5% 28.1% GAAP Research and development, net S 37,488 S 15,018 S 119,054 S Stock-based compensation (3,828) (4,442) (21,721) Amortization of purchased intangibles and favorable lease (314) (9) (647) Employee retention credit — — — 631 Non-GAAP Research and development, net S 33,346 S 10,567 S 97,317 S GAAP Selling, general and administrative S 25,887 S 24,035 S 110,273 S Stock-based compensation (4,039) (4,038) (19,219) Amortization of purchased intangibles (1,378) (1,494) (5,585) Transaction costs (30) (144) (341) Performance reserve secrow (30) (1,478) (5,247) Change in fair value of contingent consideration (205)	21.2 65,168 (21,127 (3,342 — 40,699 89,026 (16,574 (4,401) (649)
Non-GAAP Gross margin 32.3 % 14.5 % 28.1 %	21.2 65,168 (21,127 (3,342 — 40,699 89,026 (16,574 (4,401) (649)
CAAP Research and development, net S 37,488 S 15,018 S 119,054 S	65,168 (21,127 (3,342 ————————————————————————————————————
Stock-based compensation (3,828) (4,442) (21,721) Amortization of purchased intangibles and favorable lease (314) (9) (647) Employee retention credit 631 Non-GAAP Research and development, net S 33,346 S 10,567 S 97,317 S GAAP Selling, general and administrative S 25,887 S 24,035 S 110,273 S Stock-based compensation (4,039) (4,038) (19,219) Amortization of purchased intangibles (1,378) (1,494) (5,585) Transaction costs (30) (144) (341) Performance reserve escrow (30) (1,780) (5,247) Change in fair value of contingent consideration (205) 200 (1,343) Employee retention credit - - 1,080 Non-GAAP Selling, general and administrative S 20,205 S 16,779 S 79,618 S GAAP Operating expenses S 63,375 S 39,053 S 229,327 S Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	(21,127 (3,342 ————————————————————————————————————
Stock-based compensation (3,828) (4,442) (21,721) Amortization of purchased intangibles and favorable lease (314) (9) (647) Employee retention credit 631 Non-GAAP Research and development, net S 33,346 S 10,567 S 97,317 S GAAP Selling, general and administrative S 25,887 S 24,035 S 110,273 S Stock-based compensation (4,039) (4,038) (19,219) Amortization of purchased intangibles (1,378) (1,494) (5,585) Transaction costs (30) (144) (341) Performance reserve escrow (30) (1,780) (5,247) Change in fair value of contingent consideration (205) 200 (1,343) Employee retention credit - - 1,080 Non-GAAP Selling, general and administrative S 20,205 S 16,779 S 79,618 S GAAP Operating expenses S 63,375 S 39,053 S 229,327 S Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	(3,342 40,699 89,026 (16,574 (4,401 (649
Amortization of purchased intangibles and favorable lease (314) (9) (647) Employee retention credit — — — 631 Non-GAAP Research and development, net \$ 33,346 \$ 10,567 \$ 97,317 \$ GAAP Selling, general and administrative \$ 25,887 \$ 24,035 \$ 110,273 \$ Stock-based compensation (4,039) (4,038) (19,219) Amortization of purchased intangibles (1,378) (1,494) (5,585) Transaction costs (30) (144) (341) Performance reserve escrow (30) (1,780) (5,247) Change in fair value of contingent consideration (205) 200 (1,343) Employee retention credit — — — 1,080 Non-GAAP Selling, general and administrative \$ 20,205 \$ 16,779 \$ 79,618 \$ GAAP Operating expenses \$ 63,375 \$ 39,053 \$ 229,327 \$ Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692)<	89,026 (16,574 (4,401 (649
Employee retention credit	89,026 (16,574 (4,401 (649
GAAP Selling, general and administrative \$ 25,887 \$ 24,035 \$ 110,273 \$ Stock-based compensation (4,039) (4,038) (19,219) Amortization of purchased intangibles (1,378) (1,494) (5,585) Transaction costs (30) (144) (341) Performance reserve escrow (30) (1,780) (5,247) Change in fair value of contingent consideration (205) 200 (1,343) Employee retention credit — — — 1,080 Non-GAAP Selling, general and administrative \$ 20,205 \$ 16,779 \$ 79,618 \$ GAAP Operating expenses \$ 63,375 \$ 39,053 \$ 229,327 \$ Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	89,026 (16,574 (4,401 (649
Stock-based compensation (4,039) (4,038) (19,219) Amortization of purchased intangibles (1,378) (1,494) (5,585) Transaction costs (30) (144) (341) Performance reserve escrow (30) (1,780) (5,247) Change in fair value of contingent consideration (205) 200 (1,343) Employee retention credit — — — 1,080 Non-GAAP Selling, general and administrative \$ 20,205 \$ 16,779 \$ 79,618 \$ GAAP Operating expenses \$ 63,375 \$ 39,053 \$ 229,327 \$ Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	(16,574 (4,401 (649
Amortization of purchased intangibles (1,378) (1,494) (5,585) Transaction costs (30) (144) (341) Performance reserve escrow (30) (1,780) (5,247) Change in fair value of contingent consideration (205) 200 (1,343) Employee retention credit — — — 1,080 Non-GAAP Selling, general and administrative \$ 20,205 \$ 16,779 \$ 79,618 \$ GAAP Operating expenses \$ 63,375 \$ 39,053 \$ 229,327 \$ Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	(4,401 (649
Transaction costs (30) (144) (341) Performance reserve escrow (30) (1,780) (5,247) Change in fair value of contingent consideration (205) 200 (1,343) Employee retention credit — — — 1,080 Non-GAAP Selling, general and administrative \$ 20,205 \$ 16,779 \$ 79,618 \$ GAAP Operating expenses \$ 63,375 \$ 39,053 \$ 229,327 \$ Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	(649
Performance reserve escrow (30) (1,780) (5,247) Change in fair value of contingent consideration (205) 200 (1,343) Employee retention credit — — — 1,080 Non-GAAP Selling, general and administrative \$ 20,205 \$ 16,779 \$ 79,618 \$ GAAP Operating expenses \$ 63,375 \$ 39,053 \$ 229,327 \$ Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	
Change in fair value of contingent consideration (205) 200 (1,343) Employee retention credit — — — 1,080 Non-GAAP Selling, general and administrative \$ 20,205 \$ 16,779 \$ 79,618 \$ GAAP Operating expenses \$ 63,375 \$ 39,053 \$ 229,327 \$ Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	(7 122
Employee retention credit — — 1,080 Non-GAAP Selling, general and administrative \$ 20,205 \$ 16,779 \$ 79,618 \$ GAAP Operating expenses \$ 63,375 \$ 39,053 \$ 229,327 \$ Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	(7,123
Non-GAAP Selling, general and administrative \$ 20,205 \$ 16,779 \$ 79,618 \$ GAAP Operating expenses \$ 63,375 \$ 39,053 \$ 229,327 \$ Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	_
GAAP Operating expenses \$ 63,375 \$ 39,053 \$ 229,327 \$ Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	_
Stock-based compensation (7,867) (8,480) (40,940) Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	60,279
Amortization of purchased intangibles (1,692) (1,503) (6,232) Transaction costs (30) (144) (341)	154,194
Transaction costs (30) (144) (341)	(37,701
	(7,743
Performance reserve escrow (30) $(1,780)$ $(5,247)$	(649
	(7,123
Change in fair value of contingent consideration (205) 200 (1,343)	_
Employee retention credit — — 1,711	_
Non-GAAP Operating expenses \$ 53,551 \$ 27,346 \$ 176,935 \$	100,978
GAAP Operating loss \$ (47,883) \$ (37,223) \$ (177,918) \$	(135,204
Total non-GAAP adjustments 13,731 17,388 69,832	79,020
Non-GAAP Operating loss \$ (34,152) \$ (19,835) \$ (108,086) \$	(56,184
GAAP Total other income (expense), net \$ (1,603) \$ (995) \$ (1,003) \$	2,258
Change in fair value of liability classified warrants — — — —	(13,482
Loss on foreign exchange 394 488 470	4,435
Non-GAAP Total other expense, net <u>\$ (1,209)</u> <u>\$ (507)</u> <u>\$ (533)</u> <u>\$</u>	(6,789